Ángela Pedraza
Ángela Pedraza has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Juan Leandro Ramírez-Roa
Hospital Universitario Clinica San Rafael, Bogotá
1 shared publication - Laura Niño-Serna
Universidad de Antioquia Medellin Colombia
1 shared publication - María Isabel Vargas-Rumilla
Hospital Universitario Clinica San Rafael, Bogotá
1 shared publication - Olga Lucía Morales Múnera
Universidad de Antioquia, Colombia
1 shared publication
Latest Publications
- Open Access
- 27 December 2018
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 65 (4) , 341-348
Registro de inmunodeficiencias primarias en niños en un hospital de cuarto nivel. Bogotá, 2010-2016
Background: Primary immunodeficiencies are inherited diseases that compromise numerous systems and whose clinical manifestation is varied. It is an underdiagnosed pathology in Colombia.Objectives: To characterize primary immunodeficiencies in patients younger than 16 years who attended the San Rafael Clinical University Hospital, Bogota, between January 1, 2010 and July 1, 2016, as well as to provide information that enriches local, national and international statistics.Methods: Observational study of a cases series. All patients diagnosed with primary immunodeficiencies were analyzed, with a total of 75 patients.Results: Patients between one and five years of age (33 % of all cases) were the most affected, followed by patients from six to 11 months, including 17 cases; 21 cases corresponded to patients under 1 year of age; 80 % of affected children were males. Antibody deficiency was the most common type of immunodeficiency (56 %), followed by T/B lymphocyte deficiency (38 %).Conclusions: Patients with primary immunodeficiencies of the analyzed hospital had the same age and gender distribution observed in international studies. The most common primary immunodeficiency was due to antibody defects.
- 27 December 2018
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 65 (4) , 341-348
Open AccessRegistro de inmunodeficiencias primarias en niños en un hospital de cuarto nivel. Bogotá, 2010-2016
Background: Primary immunodeficiencies are inherited diseases that compromise numerous systems and whose clinical manifestation is varied. It is an underdiagnosed pathology in Colombia.Objectives: To characterize primary immunodeficiencies in patients younger than 16 years who attended the San Rafael Clinical University Hospital, Bogota, between January 1, 2010 and July 1, 2016, as well as to provide information that enriches local, national and international statistics.Methods: Observational study of a cases series. All patients diagnosed with primary immunodeficiencies were analyzed, with a total of 75 patients.Results: Patients between one and five years of age (33 % of all cases) were the most affected, followed by patients from six to 11 months, including 17 cases; 21 cases corresponded to patients under 1 year of age; 80 % of affected children were males. Antibody deficiency was the most common type of immunodeficiency (56 %), followed by T/B lymphocyte deficiency (38 %).Conclusions: Patients with primary immunodeficiencies of the analyzed hospital had the same age and gender distribution observed in international studies. The most common primary immunodeficiency was due to antibody defects.
- Open Access
- 30 July 2018
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 65 (3) , 222-232
Omalizumab en niños con asma no controlada: estudio en la “vida real” realizado en Colombia
Background: Omalizumab efficacy and safety in children older than 6 years has been clearly demonstrated in controlled clinical trials, but only in few real-life studies.Objective: To assess the response with omalizumab addition in children with moderate to severe persistent asthma in real-life conditions.Method: Observational study with a 12-month real-life follow-up in a group of 61 children older than 6 years who were assessed for asthma control before treatment was started and at 4 and 12 months.Results: After 12 months of treatment with omalizumab, there was symptom improvement both for those younger and older than 12 years (p = 0.001). There was a decrease in controller drug consumption in 73% of patients; in 61%, inhaled corticosteroid dose was reduced, and 8% discontinued its use. Inhaled corticosteroid average dose was decreased to 396 ± 298 µg, with this being statistically significant (p = 0.02).Conclusion: Omalizumab is an efficacious, safe and well-tolerated drug as add-on therapy for clinical control of moderate and severe allergic asthma that has not improved with standard therapies.
- 30 July 2018
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 65 (3) , 222-232
Open AccessOmalizumab en niños con asma no controlada: estudio en la “vida real” realizado en Colombia
Background: Omalizumab efficacy and safety in children older than 6 years has been clearly demonstrated in controlled clinical trials, but only in few real-life studies.Objective: To assess the response with omalizumab addition in children with moderate to severe persistent asthma in real-life conditions.Method: Observational study with a 12-month real-life follow-up in a group of 61 children older than 6 years who were assessed for asthma control before treatment was started and at 4 and 12 months.Results: After 12 months of treatment with omalizumab, there was symptom improvement both for those younger and older than 12 years (p = 0.001). There was a decrease in controller drug consumption in 73% of patients; in 61%, inhaled corticosteroid dose was reduced, and 8% discontinued its use. Inhaled corticosteroid average dose was decreased to 396 ± 298 µg, with this being statistically significant (p = 0.02).Conclusion: Omalizumab is an efficacious, safe and well-tolerated drug as add-on therapy for clinical control of moderate and severe allergic asthma that has not improved with standard therapies.